Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows
News
Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 ... Read more